- China has approved a new obesity drug from Pfizer (PFE), intensifying competition in a market that is expected to grow even more crowded with upcoming generic versions.
- The drug, ecnoglutide, is approved for chronic weight management in overweight or obese adults, Pfizer (
China approves Pfizer’s GLP-1 drug for weight management, intensifying market competition
